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ABSTRACT 
Background: Gastric dysplasia is classified as adenomatous/type I (intestinal 
phenotype) and foveolar or pyloric/type II (gastric phenotype) according to 
morphological (architectural and cytological) features. The immunophenotypic 
classification of dysplasia, based on the expression of mucins, CD10 and 
CDX2, recognizes the following immunophenotypes: intestinal (MUC2, CD10 
and CDX2); gastric (MUC5AC and/or MUC6, absent of CD10 and absent or low 
expression of CDX2); hybrid (gastric and intestinal markers) and null. 
Methods: Sixty-six cases of non-polypoid epithelial dysplasia of the stomach 
were classified according to morphological features (histotype and grade) and 
immunophenotype. Immunohistochemical staining was performed with 
antibodies against MUC2, MUC5AC, MUC6, CD10, CDX2, chromogranin, 
synaptophysin, Ki-67 and TP53. HER2 alterations were analysed by 
immunohistochemistry and silver-enhanced in situ hybridization (SISH).  
Results: By conventional histology, dysplasia was classified as 
adenomatous/intestinal (n=42; 64%) and foveolar or pyloric/gastric (n=24; 36%) 
and graded as low-grade (n=37; 56%) and high-grade (n=29; 44%). 
Immunophenotypic classification showed intestinal (n=22; 33.3%), gastric 
(n=25; 37.9%), hybrid (n=17; 25.8%) or null (n=2; 3.0%) phenotypes. In 20 
cases a coexistent intramucosal carcinoma was identified. 
The intestinal immunophenotype was shown to be significantly associated with 
low-grade dysplasia (p=0.001), high expression of CDX2 (p=0.015), TP53 
(p=0.034), synaptophysin (p=0.003) and chromogranin (p<0.0001); the gastric 
immunophenotype was significantly associated with high-grade dysplasia 
(p=0.001), high Ki-67 proliferative index (p=0.05) and coexistence of 
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intramucosal carcinoma (p=0.013). HER2 amplification was observed in 3 
cases, typed as gastric or hybrid.  
Conclusions: Epithelial non-polypoid dysplasia of the stomach with gastric 
immunophenotype shows features of biological aggressiveness and may 
represent the putative precursor lesion in a pathway of gastric carcinogenesis 
originated de novo from the native gastric mucosa, leading to gastric type 
adenocarcinoma.  
 
MINI ABSTRACT 
Epithelial dysplasia of the stomach encompasses two major 
immunophenotypes, intestinal and gastric, the latter significantly associated with 
features of biological aggressiveness: high-grade, high proliferative index and 
coexistent carcinoma.  
 
Key words: Gastric carcinogenesis; dysplasia; HER2; immunophenotype; 
mucins. 
 
4 
INTRODUCTION 
At present, gastric carcinoma (GC) has a significant morbi-mortality impact, 
being the fourth most incident cancer worldwide and the second deadliest one 
(1). 
According to Laurén's classification (2), there are two main subtypes of 
GC - intestinal and diffuse - that differ in  epidemiology, pathogenesis, 
morphology and molecular features  (2, 3). According to the Correa model, 
gastric cancer develops along a cascade of lesions encompassing Helicobacter 
pylori induced chronic superficial gastritis, chronic atrophic gastritis, intestinal 
metaplasia, dysplasia, and ultimately invasive adenocarcinoma (4). Gastric 
dysplasia is neoplastic in nature and is a direct precursor of gastric carcinoma, 
as well as a risk factor of carcinoma in other locations of the stomach (5, 6). 
Dysplasia is graded as low- and high-grade on the basis of architectural 
and cell features. Further, according to the histomorphological profile, dysplasia 
may be classified as adenomatous/type I (intestinal phenotype) and foveolar or 
pyloric/type II (gastric phenotype). The two types may be distinguished by the 
immunoexpression of mucins, CD10 and CDX2 (intestinal/adenomatous: 
MUC2, CD10, and CDX2; gastric/foveolar: MUC5AC and/or MUC6, absence of 
CD10 and low or absent expression of CDX2) (7-9). Cases with hybrid 
differentiation may also occur as well as null cases in which there is no 
expression of the aforementioned markers (8). 
A relationship has been reported between the histological grade and the 
immunohistochemical profiles of dysplasia: in one study, 81.8%  of low-grade 
dysplasia expressed intestinal markers, and 72.2% of high-grade dysplasia 
showed markers of gastric differentiation with variable expression of intestinal 
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markers (10). In another study, foveolar and hybrid subtypes were also 
significantly associated with high-grade dysplasia (8). 
In this study we aimed at analysing the relationship between different 
types of gastric dysplasia (based on histotypes and grading) and the 
immunohistochemical profile according to the expression of markers of cell 
differentiation (MUC5AC, MUC6, MUC2, CD10). The expression of CDX2, Ki-
67, TP53, HER2 and neuroendocrine markers (chromogranin and 
synaptophysin) was also evaluated. 
 
MATERIALS AND METHODS 
A series of 66 cases of non-polypoid epithelial dysplasia of the stomach 
identified in Endoscopic Submucosal Dissection (ESD) specimens were 
retrieved retrospectively from the files of the Department of Pathology, Centro 
Hospitalar São João, between June/2010 and June/2013. In 20 cases a 
coexistent intramucosal carcinoma was identified. The study was approved by 
the Ethical Committee of the Hospital. The clinicopathological features of the 
cases are summarized in Table 1. 
Tissues were fixed in neutral buffered 10% formalin, embedded in 
paraffin and cut into 3 µm-thick sections.  
The lesions were classified in H&E stained slides as: adenomatous/type I 
(intestinal phenotype) and foveolar or pyloric/type II (gastric phenotype), 
according to the WHO classification (3). The adenomatous/intestinal subtype 
resembles colonic adenomas, with crowded, tubular glands lined by atypical 
columnar cells with overlapping, pencillate, hyperchromatic and/or pleomorphic 
nuclei, with pseudostratification and mucin. The foveolar or pyloric/gastric 
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phenotype is characterized by cuboid/low columnar cells, with round to oval 
nuclei and clear or eosinophilic cytoplasm. 
The grade of the dysplasia was evaluated according to WHO 2010 
criteria (3): low-grade dysplasia shows minimal architectural disarray and only 
mild to moderate cytological atypia; the nuclei are elongated/oval, polarized and 
basally-located and the mitotic activity is mild to moderate; high-grade dysplasia 
presents pronounced architectural disarray, such as complex branching or 
fusion of glands; the neoplastic cells are usually cuboidal, rather than columnar, 
with a high nuclear/cytoplasm ratio, high number of mitoses, occasionally 
atypical, and nuclei within the luminal zone of the epithelium with loss of 
polarity. The diagnosis of invasive carcinoma was performed when invasion of 
the lamina propria or deeper occurred.  
Immunohistochemical staining was performed with antibodies against 
MUC2, MUC5AC, MUC6, CD10, CDX2, chromogranin, synaptophysin, Ki-67, 
HER2 and TP53 (Table 2). Samples were processed in the automatic 
equipment Benchmark ULTRA using the Ultraview Universal DAB kit (Ventana 
Medical Systems, Roche group). Each sample was heated and deparaffinized, 
followed by antigen recovery through heat and high-pH buffer solution. Each 
primary antibody was incubated in an individually optimized time and 
temperature, followed by application of the detection system and contrast with 
hematoxilin and bluing reagent from the same manufacturer. 
Immunoreactivity was scored as follows: the immunoexpression of 
MUC2, MUC5AC, MUC6, CD10, synaptophysin and chromogranin was scored 
as positive when ≥5% of the dysplastic cells displayed immunoreactivity; HER2 
immunoexpression was scored according to Fassan et al (11): 0 – absence of 
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immunoreactivity; 1+ – tumour cell cluster with faint or barely perceptible 
membrane reactivity irrespective of percentage of immunoreactive cells; 2+ – 
tumour cell cluster with weak to moderate (complete, lateral or basolateral) 
reactivity irrespective of the percentage of immunoreactive cells; 3+ – tumour 
cell cluster with moderate to strong (complete, lateral or basolateral) reactivity 
irrespective of the percentage of immunoreactive cells; for scoring purposes any 
nuclear or cytoplasmatic backgroung staining was disregarded. The 
immunoexpression of CDX2 was considered positive when ≥25% of the 
dysplatic cells displayed immunoreactivity (9); immunoexpression of Ki-67 and 
TP53 was classified as absent/low when immunoreactivity was displayed in 
<50% of the dysplastic cells, and high in the presence of ≥50% positive cells 
(12). 
The detection of the number of copies of the HER2 gene was performed 
in the cases scored as 2+ and 3+ by immunohistochemistry with SISH 
automatized technique using the BenchMark XT equipment and the INFORM™ 
HER2 SISH probe, manufactured by Ventana Medical Systems. The 
HER2/Chr17 ratio of each case was calculated using a minimum of 40 cells in 
two independent areas of dysplasia. Cases were assigned a score based on the 
ASCO/CAP guideline recommendations for HER2 testing in breast cancer as 
follows (13): negative - ratio HER2:Cr17<2.0 with <4 copies of HER2 gene; 
borderline - ratio HER2:Cr17<2.0 with ≥4 and <6 copies of HER2 gene; positive 
- ratio HER2:Cr17<2.0 with ≥6 copies of HER2 gene or ratio HER2:Cr17≥2.0. 
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Statistical Analysis 
Appropriate statistical methods were used regarding the type of sample and its 
distribution. The data was analysed with SPSS software v. 19.0 (SPSS 
Software, Chicago, IL, USA), using chi-square or Fischer’s test. P-value <0.05 
was considered statistically significant.  
 
RESULTS 
The study group was composed of 66 cases (Table 1), classified by 
conventional histology in H&E stained slides as foveolar or pyloric/gastric 
(n=24; 36%) or adenomatous/intestinal (n=42; 64%) (Fig.1) and graded as low-
grade (n=37; 56%) or high-grade (n=29; 44%). According to the 
immunophenotype, the cases were classified as gastric type (n=25; 37.9%) 
(Fig. 2 – a, c, e, g, i), intestinal (n=22; 33.3%) (Fig. 2 – b, d, f, h, j), hybrid (n=17; 
25.8%) or null (n=2, 3.0%). The latter were not considered for subsequent 
analysis. 
Table 3 summarizes the expression of the different markers in the three 
immunophenotypes of gastric dysplasia. Statistically significant differences were 
observed between the immunophenotypes regarding the expression of MUC2 
(p=0.002), CD10 (p<0.0001), MUC5AC (p<0.0001) and MUC6 (p<0.0001). 
Cases with low/absent expression of CDX2 were observed only in the gastric 
immunophenotype (p=0.015). 
The frequency of cases with high expression of Ki-67 was significantly 
higher in the gastric and hybrid (84.0% and 94.1%, respectively) than in the 
intestinal (63.6%) immunophenotypes (p=0.05). 
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The frequency of cases with high expression of TP53 was significantly 
higher in the intestinal and hybrid (52.9% and 52.9%, respectively) than in the 
gastric (16.0%) immunophenotypes (p=0.034). 
The expression of HER2 (2+ and 3+) was observed in 11 cases with 
gastric or hybrid immunophenotypes (28.0% and 23.5%, respectively) and not 
detected in the intestinal immunophenotype (p=0.029). 
Amplification of HER2 gene was observed only in three cases, 
immunophenotyped as gastric (n=1) and hybrid (n=2). 
Regarding the neuroendocrine markers, the frequency of the expression 
of synaptophysin was significantly higher in intestinal (81.8%) than in hybrid and 
gastric (58.8% and 32.0%, respectively) immunophenotypes (p=0.003). Similar 
observations were made for the expression of chromogranin, displayed 
predominantly in intestinal (95.2%) in comparison with hybrid and gastric 
(70.6% and 28.0%, respectively) immunophenotypes (p<0.0001). In some 
cases, immunophenotyped as intestinal, small nests of neuroendocrine cells 
were observed. 
Table 4 shows the relationship between the immunophenotypes and the 
histotypes of gastric dysplasia (adenomatous/intestinal and foveolar or 
pyloric/gastric), and grade (low- and high-grade). The frequency of high-grade 
dysplasia was significantly higher in the gastric immunopenotype (68.0%) than 
in the other immunophenotypes (47.1% and 13.6%, in hybrid and intestinal, 
respectively). Within cases with intestinal immunophenotype, dysplasia was 
graded as low in most cases (86.4%) (p=0.001). Gastric immunophenotype 
encompassed cases classified by conventional histology as gastric (72.0%) and 
intestinal (28.0%); hybrid immunophenotype encompassed cases classified by 
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histology as gastric (35.3%) and intestinal (64.7%) and all cases of the intestinal 
immunophenotype displayed features of the adenomatous/intestinal histotype 
(p<0.0001). 
Table 5 shows the relationship between the presence of the coexistent 
intramucosal adenocarcinoma and the features of dysplasia (grade, histo and 
immunophenotypes). In 20 of 66 cases (30.3%), there was a coexistent 
carcinoma at the periphery of the dysplastic lesions, the latter displaying the 
following features: high-grade (75.0%; p=0.001); gastric histotype (60.0%; 
p=0.024); gastric immunophenotype (65.0%, 20.0% and 15.0% for gastric, 
hybrid and intestinal immunophenotypes, respectively; p=0.013). Gastric 
dysplasia at the periphery of invasive carcinoma, when compared with gastric 
dysplasia in the absence of invasive carcinoma, displayed significantly lower 
frequency of expression of synaptophysin and chromogranin (30.0% and 
40.0%; p=0.006 and p=0.025, respectively).  
 
DISCUSSION 
Gastric carcinogenesis is a complex process, still requiring the elucidation of 
putative distinct pathways. According to the so-called Correa model (4), gastric 
carcinogenesis is a multistep and multifactorial process that, in many cases, 
appears to involve a progression from normal mucosa, through chronic atrophic 
gastritis and intestinal metaplasia, to dysplasia and invasive carcinoma. 
However, evidence from literature points to the possibility of the existence of 
alternative pathways in which intestinal metaplasia may not play a role. 
Evidence stems mainly from the study of tiny early gastric carcinomas arising in 
non-metaplastic mucosa, as described by Japanese authors (14, 15) as well as 
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the studies of the expression of markers of gastric differentiation in dysplasia 
and gastric adenocarcinoma (7, 10, 16, 17). The latter demonstrate that both 
types of lesions may express, predominantly or exclusively, markers of gastric 
differentiation, raising the possibility of an origin in native gastric mucosa, rather 
than in intestinal metaplastic lesions. It remains to be elucidated the role of 
spasmolytic polypeptide-expressing metaplasia (SPEM) in the pathogenesis of 
the lesions with gastric immunophenotype. Other evidences stem from 
hereditary gastric cancer models (Hereditary Diffuse Gastric Cancer and Gastric 
Adenocarcinoma and Proximal Polyposis of the Stomach – HDGC and GAPPS) 
in which gastric carcinoma, diffuse/poorly cohesive type and intestinal/tubular 
types, respectively, originate in non-metaplastic gastric epithelium (fundic gland 
polyps in the case of GAPPS) (18, 19).  
Our study provides additional evidence in favour of de novo neoplastic 
transformation from native gastric mucosa (37.9% of the dysplastic lesions 
displayed “pure” gastric immunophenotype).  
Another relevant issue is the risk of malignant transformation of the 
different types of gastric dysplasia. Our results show that within the group of 
cases immunophenotyped as gastric, the majority were classified as high-grade 
dysplasia (68.0%; p=0.001). At variance, within cases immunophenotyped as 
intestinal, low-grade dysplasia was the most frequent (86.4%; p=0.001). These 
findings are in keeping with those recently reported by Nishimura et al (14),  but 
differ from the results reported by Abraham et al (20), the latter showing that 
intestinal-type adenomas were more likely than gastric-type adenomas to 
display high-grade dysplasia and adenocarcinoma in the polyps. A major 
difference from this stud concerns the fact that while the series studied by 
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Abraham et al (20) was constituted by polypoid adenomas, our series is 
constituted by non-polypoid dysplasia. 
HER2 amplification was observed in three cases, immunophenotyped as 
gastric or hybrid. These findings show that HER2 amplification may be an early 
event in gastric carcinogenesis as observed by Fassan et al (11). 
The results herein obtained in dysplasia with gastric immunophenotype 
(higher frequency of high-grade lesions, expression and amplification of HER2) 
suggest that this type of dysplasia may be an important player in gastric 
carcinogenesis.  
The high frequency of cases with high proliferative index (Ki-67) in 
gastric and hybrid immunophenotypes (84.0% and 94.1%, respectively) when 
compared with the intestinal immunophenotype (63.6%; p=0.05) is in keeping 
with the features of aggressiveness identified in dysplastic lesions with gastric 
differentiation. At variance with other studies (21, 22) we have not found a 
significant difference in the Ki-67 proliferation index according to the grade of 
dysplasia. 
In this study, we observed that the expression of CDX2 is correlated with 
the intestinal immunophenotype (100% of the cases), in keeping with data 
previously reported (9). In accordance with Park et al (9), a decreased 
expression of CDX2 was observed in cases with gastric immunophenotype 
(80% of the cases; decreased intensity of immunoreactivity). However, there is 
controversy in the literature regarding the expression of CDX2 in gastric 
dysplasia, probably reflecting the lack of sub-typing of dysplasia in the different 
studies (9, 23, 24). 
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In some cases with intestinal immunophenotype small nests of 
neuroendocrine cells were observed, qualifying for neuroendocrine hyperplasia 
as reported in the literature (25, 26). It is likely that adenomatous/intestinal 
dysplasia and neuroendocrine hyperplasia both arise in the setting of chronic 
atrophic gastritis, as previously suggested in neuroendocrine hyperplasia within 
gastric hyperplastic polyps (27). However, further studies are needed to 
elucidate the biological meaning of this event. 
In the present study we observed that higher expression of TP53 
significantly correlated with the intestinal immunophenotype (p=0.034) and was 
also more frequently observed in high-grade dysplasia, though this association 
was not significant (p=0.070 – data not shown). In previous studies, it was 
observed an increased frequency of TP53 overexpression along the progress of 
gastric carcinogenesis. However, in these studies the immunohistochemical 
sub-typing of gastric dysplasia was not performed (28). Kushima et al (29) 
showed that the frequency of TP53 expression was significantly higher in 
intestinal-type adenomas than in gastric-type adenomas, in keeping with the 
present study, and was higher in high-grade dysplasia than in low-grade 
dysplasia, leading to the suggestion that TP53 alterations occur earlier in the 
carcinogenetic sequence along intestinal rather than gastric differentiation 
pathway (29).  
Summing up, our results point to the existence of two major types of non-
polypoid dysplasia in the stomach. The gastric immunophenotype is significantly 
associated with high-grade dysplasia (p=0.001), high proliferative index (Ki-67) 
(p=0.050) and coexistence of intramucosal adenocarcinoma (p=0.013). The 
intestinal immunophenotype was shown to be significantly associated with low-
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grade dysplasia (p=0.001), overexpression of TP53 (p=0.034) and 
neuroendocrine markers (p=0.003 for synaptophysin and p<0.0001 for 
chromogranin). 
Recently, gene expression profiling using mRNA consensus clustering 
has revealed three distinct gastric cancer subtypes – mesenchymal, 
proliferative and metabolic (30). The metabolic subtype is characterized by the 
expression of genes normally expressed in gastric mucosa, involved in 
metabolic processes and digestion, and the expression of trefoil peptides (30) 
that are co-expressed in normal mucosa of the stomach with gastric mucins. 
These data are in keeping with the results of our previous studies showing the 
expression of trefoil peptides (and gastric mucins) in a subset of dysplastic and 
adenocarcinomatous lesions of the stomach (7, 16, 17), supporting the 
existence of a pathway of gastric carcinogenesis with gastric differentiation. 
In face of the evidence we collected and that from the literature, we feel 
tempted to suggest that non-polypoid epithelial dysplasia of the stomach with 
gastric immunophenotype may represent the putative precursor lesion in a 
pathway of gastric carcinogenesis originated de novo from the native gastric 
mucosa, leading to a subset of glandular gastric carcinomas with gastric 
differentiation.  
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TABLES 
Table 1. Clinicopathological features of the series of cases. 
 
Age (y, mean ± SD) 65.95 ± 10.93 
Sex 
 
Male 34 
Female 32 
Tumour size (cm, mean ± SD) 2.51 ± 2.23 
Location  
Body/fundus 20 (31.3%) 
Antrum/pylorus 44 (68.7%) 
                                                          
 Missing data for location (2 cases). 
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Table 2. Primary antibodies and immunohistochemistry conditions used in this 
study. 
Antibody Clone 
Antigen 
Retrieval 
Conditions 
Dilution 
Incubation 
time (min) 
at 37ºC 
Localization Source 
CDX2 EPR2764Y 
64 minutes 
at 96ºC 
Pre-
diluted 
28 Nuclear 
Cell Marque, 
USA 
MUC2 Ccp58 
52 minutes 
at 96ºC 
1:100 36 Cytoplasmatic 
Novocastra, 
UK 
MUC5AC MRQ-19 
36 minutes 
at 96ºC 
Pre-
diluted 
24 Cytoplasmatic 
Cell Marque, 
USA 
MUC6 MRQ-20 
36 minutes 
at 95ºC 
Pre-
diluted 
28 Cytoplasmatic 
Cell Marque, 
USA 
CD10 SP67 
64 minutes 
at 95ºC 
Pre-
diluted 
40 
Membrane 
(Brush 
border) 
Ventana, 
USA 
Chromogranin NS55 
52 minutes 
at 96ºC 
1:300 36  Cytoplasmatic 
Invitrogen, 
USA 
Synaptophysin SP11 
36 minutes 
at 95ºC 
1:150 32  Cytoplasmatic 
Neomarkers, 
USA 
Ki-67 SP6 
36 minutes 
at 95ºC 
1:400 32  Nuclear 
Neomarkers, 
USA 
HER2 4B5 
36 minutes 
at 95ºC 
Pre-
diluted 
12  Membrane 
Ventana, 
USA 
TP53 318-6-11 
52 minutes 
at 96ºC 
1:200 32  Nuclear 
DAKO, 
Denmark 
                                                          
 Antigen retrieval performed with CC1 (Tris/borate/EDTA buffer with pH 8.4  - Ventana Medical Systems, 
catalogue number 950-124). 
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Table 3. Expression of the different markers according to the three 
immunophenotypes of gastric dysplasia. 
 Immunophenotype  
p-value  Gastric Hybrid Intestinal 
MUC2     
<5% 25 (100%) 10 (58.8%) 14 (63.6%)   
≥5% 0 7 (41.2%) 8 (36.4%)  .002 
MUC5AC     
<5% 3 (12.0%) 8 (47.1%) 22 (100%)   
≥5% 22 (88.0%) 9 (52.9%) 0  .000 
MUC6     
<5% 2 (8.7%) 1 (5.9%) 22 (100%)   
≥5% 21 (91.3%) 16 (94.1%) 0  .000 
CD10     
<5% 24 (96.0%) 3 (17.6%) 2 (9.1%)   
≥5% 1 (4.0%) 14 (82.4%) 20 (90.9%)  .000 
CDX2     
<25% 5 (20.0%) 0 0   
≥25% 20 (80.0%) 17 (100%) 22 (100%) .015 
Ki-67     
<50% 4 (16.0%) 1 (5.9%) 8 (36.4%)   
≥50% 21 (84.0%) 16 (94.1%) 14 (63.6%)  .050 
TP53     
<50% 21 (84.0%) 8 (47.1%) 13 (59.1%)   
≥50% 4 (16.0%) 9 (52.9%) 9 (52.9%) .034 
HER2     
0, 1+ 18 (72.0%) 13 (76.5%) 22 (100%)  
2+, 3+ 7 (28.0%) 4 (23.5%) 0  .029 
Synaptophysin     
<5% 17 (68.0%) 7 (41.2%) 4 (18.2%)   
≥5% 8 (32.0%) 10 (58.8%) 18 (81.8%)  .003 
Chromogranin     
<5% 18 (72.0%) 5 (29.4%) 1 (4.8%)   
≥5% 7 (28.0%) 12 (70.6%) 20 (95.2%)  .000 
                                                          
 Missing data for MUC6 (2 cases) and chromogranin (1 case). 
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Table 4. Relation between immunophenotype and the histotype and grade of 
dysplasia. 
 Immunophenotype  
p-value Gastric Hybrid Intestinal 
Histotype     
Gastric 18 (72.0%) 6 (35.3%) 0   
Intestinal 7 (28.0%) 11 (64.7%) 22 (100%) .000 
Grade     
Low-Grade 8 (32.0%) 9 (52.9%) 19 (86.4%)   
High-Grade 17 (68.0%) 8 (47.1%) 3 (13.6%)  .001 
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Table 5. Comparison of the features of gastric dysplasia as isolated lesion or at 
the periphery of intramucosal gastric adenocarcinoma. 
 Adenocarcinoma  
p-value Absent Present 
Grade of 
Dysplasia 
   
Low-Grade 31 (70.5%) 5 (25.0%)   
High-Grade 13 (29.5%) 15 (75.0%) .001 
Histotype    
Gastric 12 (27.3%) 12 (60.0%)   
Intestinal 32 (72.7%) 8 (40.0%) .024 
Immunophenotype    
Gastric 12 (27.3%) 13 (65.0%)   
Hybrid 13 (29.5%) 4 (20.0%)   
Intestinal 19 (43.2%) 3 (15.0%) .013 
HER2    
0, 1+ 40 (90.9%) 13 (65.0%)  
2+, 3+ 4 (9.1%) 7 (35.0%) .027 
Synaptophysin    
<5% 14 (31.8%) 14 (70.0%)   
≥5% 30 (68.2%) 6 (30.0%) .006 
Chromogranin    
<5% 12 (27.9%) 12 (60.0%)   
≥5% 31 (72.1%) 8 (40.0%)  .025 
                                                          
 Missing data for chromogranin (1 case). 
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FIGURE LEGENDS 
Fig. 1 Histotypes of gastric dysplasia: (a) foveolar/gastric type, displaying 
cuboid/low columnar cells, with round to oval nuclei and eosinophylic cytoplasm 
(H&E, original magnification 100X); (b) adenomatous/intestinal type, displaying 
tubular glands lined by columnar cells with overlapping, pencillated nuclei with 
pseudostratification (H&E, original magnification 100X) 
 
Fig. 2 Immunophenotypes of gastric dysplasia: gastric immunophenotype 
displaying (a) foveolar and pyloric/gastric histotype, high expression of (c)  
MUC5AC and (e) MUC6 and lack of expression of (g) MUC2 and (i) CD10 (H&E 
(a) and IHC (c, e, g and i), original magnification 40X); intestinal 
immunophenotype displaying (b) adenomatous/intestinal histotype, lack of 
expression of (d) MUC5AC and (f) MUC6, and expression of (h) MUC2 (inset: 
MUC2 is expressed in goblet cells) and (j) CD10 (inset: CD10 is exhibited at the 
apical pole of dysplastic cells) (H&E (b) and IHC (d, f, h and j), original 
magnification 100X) 
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